Characterization of the treatment prescribed to patient with ulcer of diabetic foot.

Abstract

The Diabetes Mellitus is a problem of health in Cuba, and a rate of patient controlled is reported in the year 2011 of 32.2 x 1000 inhabitants in our county. The ulcer of diabetic foot (UDP) it is one of their more frequent complications, with a lightly superior annual incidence to 2.0%, it calculates that it rises between 5.0% and 7.5% in those that present outlying neuropathy. The intralesional infiltration of epidermal growth factor, Heberprot P®, produced by the Center of Genetic Engineering and Biotechnology (CGEB) that forms part of the Basic Medications in Cuba, it was able to increase the percentage of patients that wich finished with granulation in 88.2% and healing of the lesion, as well as the decrease of the number and amputation level, in the GTH "Dr. Agostinho Neto" of Guantanamo.